MEP21908A - Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same - Google Patents

Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same

Info

Publication number
MEP21908A
MEP21908A MEP-219/08A MEP21908A MEP21908A ME P21908 A MEP21908 A ME P21908A ME P21908 A MEP21908 A ME P21908A ME P21908 A MEP21908 A ME P21908A
Authority
ME
Montenegro
Prior art keywords
preparation
rimonabant
pharmaceutical compositions
compositions containing
containing same
Prior art date
Application number
MEP-219/08A
Other languages
English (en)
Croatian (hr)
Inventor
Alain Alcade
Gilles Anne-Archard
Corinne Gavory
Olivier Monnier
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of MEP21908A publication Critical patent/MEP21908A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pronalazak se odnosi na novi kristalni polimorf rimonabanta, metode njegovog dobijanja i farmaceutski sastav pomenutog polimorfa.
MEP-219/08A 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same MEP21908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
PCT/FR2002/003765 WO2003040105A1 (fr) 2001-11-08 2002-11-04 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
MEP21908A true MEP21908A (en) 2010-06-10

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-219/08A MEP21908A (en) 2001-11-08 2002-11-04 Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same

Country Status (33)

Country Link
US (2) US20050043356A1 (bs)
EP (1) EP1446384A1 (bs)
JP (2) JP4181994B2 (bs)
KR (2) KR20090089485A (bs)
CN (1) CN100412063C (bs)
AP (1) AP1830A (bs)
AR (1) AR037253A1 (bs)
AU (1) AU2002350869B2 (bs)
BR (1) BR0213931A (bs)
CA (1) CA2464145A1 (bs)
CO (1) CO5580827A2 (bs)
CR (1) CR7333A (bs)
EA (1) EA006771B1 (bs)
EC (1) ECSP045088A (bs)
FR (1) FR2831883B1 (bs)
GE (1) GEP20063894B (bs)
HR (1) HRP20040403A2 (bs)
HU (1) HUP0402043A3 (bs)
IL (2) IL161533A0 (bs)
IS (1) IS7226A (bs)
MA (1) MA27080A1 (bs)
ME (1) MEP21908A (bs)
MX (1) MXPA04004394A (bs)
NO (1) NO326648B1 (bs)
NZ (1) NZ532369A (bs)
OA (1) OA12721A (bs)
PL (1) PL369372A1 (bs)
RS (1) RS36904A (bs)
TN (1) TNSN04079A1 (bs)
TW (1) TW200302824A (bs)
UA (1) UA76776C2 (bs)
WO (1) WO2003040105A1 (bs)
ZA (1) ZA200402999B (bs)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
WO2008044153A2 (en) * 2006-08-29 2008-04-17 Medichem, S.A. Improved method for synthesizing rimonabant
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them
JP5437812B2 (ja) * 2006-12-18 2014-03-12 ７ティーエム ファーマ エイ／エス Ｃｂ１受容体モジュレーター
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
BRPI0806498A2 (pt) 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EP1944297A1 (en) * 2007-01-09 2008-07-16 Miklós Vértessy Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009153804A1 (en) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Process for preparing form i of rimonabant
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
AU2002331595A1 (en) * 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
IS7226A (is) 2004-04-19
AP1830A (en) 2008-02-22
KR20090089485A (ko) 2009-08-21
CN1582278A (zh) 2005-02-16
JP2005508383A (ja) 2005-03-31
MXPA04004394A (es) 2004-08-11
HRP20040403A2 (en) 2004-08-31
HUP0402043A3 (en) 2009-07-28
TNSN04079A1 (fr) 2006-06-01
ECSP045088A (es) 2004-06-28
EA200400491A1 (ru) 2004-12-30
CN100412063C (zh) 2008-08-20
OA12721A (fr) 2006-06-27
GEP20063894B (en) 2006-08-10
EA006771B1 (ru) 2006-04-28
ZA200402999B (en) 2005-04-20
PL369372A1 (en) 2005-04-18
BR0213931A (pt) 2004-09-08
NZ532369A (en) 2005-10-28
TW200302824A (en) 2003-08-16
NO20041879D0 (no) 2004-05-07
IL161533A0 (en) 2004-09-27
US20050043356A1 (en) 2005-02-24
KR20050043774A (ko) 2005-05-11
NO20041879L (no) 2004-06-08
UA76776C2 (uk) 2006-09-15
NO326648B1 (no) 2009-01-26
JP4931874B2 (ja) 2012-05-16
CO5580827A2 (es) 2005-11-30
CA2464145A1 (en) 2003-05-15
HUP0402043A2 (hu) 2005-01-28
WO2003040105A1 (fr) 2003-05-15
RS36904A (en) 2006-10-27
JP2009035547A (ja) 2009-02-19
MA27080A1 (fr) 2004-12-20
CR7333A (es) 2008-09-23
EP1446384A1 (fr) 2004-08-18
AU2002350869B2 (en) 2007-07-26
AR037253A1 (es) 2004-11-03
FR2831883A1 (fr) 2003-05-09
IL161533A (en) 2010-05-31
US20100190827A1 (en) 2010-07-29
JP4181994B2 (ja) 2008-11-19
FR2831883B1 (fr) 2004-07-23
AP2004003024A0 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
MEP21908A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same
SE0101675D0 (sv) Novel composition
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
NO20044221L (no) Nye forbindelser
BRPI0519726B8 (pt) composto de hemidrato de (r)-8-cloro-1-metil-2,3,4,5-tetraidro-1h-3-benzazepina, composição compreendendo o referido composto e seus usos
LV12735A (en) Manufacture and pharmaceutical compositions thereof
HK1058934A1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
HUP0401141A2 (hu) A fluvasztatin-nátrium kristályos formái, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
IL160171A0 (en) Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
UA83648C2 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
NO20055749L (no) Sulfamat benzotiofenderivater som steroid sulfatase inhibitorer
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
NO20052197L (no) Fremgangsmate for fremstilling av pyrazol
NO20041573L (no) Aralkyl-tetrahydro-pyridiner, deres fremstilling og farmasoytiske preparater inneholdende de samme
MX2007007899A (es) Nuevos derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO20055495L (no) 4-(4-trans-hydroksysykloheksyl)amino-2-fenyl-7H-pyrrolo[2,3-d]-pyrimidinhydrogenmesylat og dets polymorfe former
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
NO20055530L (no) NK-2-antagonistiske basiske lineaere forbindelser og preparater som inneholder dem
GEP20094744B (en) Novel naphthalenic derivatives, method for the preparation thereof, and pharmaceutical compositions containing same